ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.248C>A (p.Ala83Asp)

dbSNP: rs876661197
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000479690 SCV000567923 uncertain significance not provided 2016-03-22 criteria provided, single submitter clinical testing This variant is denoted MSH6 c.248C>A at the cDNA level, p.Ala83Asp (A83D) at the protein level, and results in the change of an Alanine to an Aspartic Acid (GCT>GAT). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. MSH6 Ala83Asp was not observed in approximately 4,900 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Alanine and Aspartic Acid differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. MSH6 Ala83Asp occurs at a position that is not conserved and is not located in a known functional domain (Kariola 2002, Terui 2013). In silico analyses predict that this variant is unlikely to alter protein structure or function. Based on currently available evidence, it is unclear whether MSH6 Ala83Asp is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Invitae RCV001041899 SCV001205550 uncertain significance Hereditary nonpolyposis colorectal neoplasms 2023-04-01 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MSH6 protein function. ClinVar contains an entry for this variant (Variation ID: 419824). This variant has not been reported in the literature in individuals affected with MSH6-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces alanine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 83 of the MSH6 protein (p.Ala83Asp).
Ambry Genetics RCV002431398 SCV002740469 uncertain significance Hereditary cancer-predisposing syndrome 2020-11-24 criteria provided, single submitter clinical testing The p.A83D variant (also known as c.248C>A), located in coding exon 1 of the MSH6 gene, results from a C to A substitution at nucleotide position 248. The alanine at codon 83 is replaced by aspartic acid, an amino acid with dissimilar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Baylor Genetics RCV003464002 SCV004197650 uncertain significance Endometrial carcinoma 2023-10-10 criteria provided, single submitter clinical testing
All of Us Research Program, National Institutes of Health RCV004002318 SCV004833271 uncertain significance Lynch syndrome 2023-08-15 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.